Peptron, Inc. (KOSDAQ:087010)

Market Cap	5.77T +154.3%
Revenue (ttm)	6.19B +157.2%
Net Income	-14.19B
EPS	-623.26
Shares Out	23.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	277,200
Average Volume	327,746
Open	256,500
Previous Close	274,000
Day's Range	243,000 - 264,500
52-Week Range	85,000 - 392,500
Beta	0.85
RSI	43.97
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 087010

Financial Performance

In 2024, Peptron's revenue was 3.15 billion, a decrease of -5.68% compared to the previous year's 3.34 billion. Losses were -22.03 billion, 38.4% more than in 2023.